Items where authors include "Birtle, A."

Article

Huddart, R., Hafeez, S., Griffin, C. et al. (24 more authors) (2025) Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial. European Urology, 87 (1). pp. 60-70. ISSN 0302-2838

Rescigno, P., Porta, N., Finneran, L. et al. (26 more authors) (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205. 114103. ISSN 0959-8049

Huddart, R., Hafeez, S., Omar, A. et al. (25 more authors) (2023) Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. Clinical Oncology, 35 (9). pp. 586-597. ISSN 0936-6555

Parker, C.C., James, N.D. orcid.org/0000-0002-7314-8204, Brawley, C.D. orcid.org/0000-0003-3641-278X et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277

Crabb, S.J., Danson, S. orcid.org/0000-0002-3593-2890, Catto, J.W.F. orcid.org/0000-0003-2787-8828 et al. (16 more authors) (2021) Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clinical Cancer Research, 27 (7). pp. 1882-1892. ISSN 1078-0432

Fulton, B., Jones, R., Powles, T. et al. (8 more authors) (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21. 344. ISSN 1745-6215

Birtle, A., Johnson, M., Chester, J. et al. (21 more authors) (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet, 395 (10232). pp. 1268-1277. ISSN 0140-6736

Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30 (12). pp. 1992-2003. ISSN 0923-7534

James, N., Pirrie, S., Pope, A. et al. (17 more authors) (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 20. 53. ISSN 1366-5278

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096

James, N.D., Pirrie, S.J., Pope, A.M. et al. (19 more authors) (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2 (4). p. 493. ISSN 2374-2437

Proceedings Paper

Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: Disease control data. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S704-S705.

Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: patient reported outcomes. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S331-S332.